Identification of iron metabolism-related genes as prognostic indicators for papillary thyroid carcinoma: a retrospective study.
[BACKGROUND] The thyroid cancer subtype that occurs more frequently is papillary thyroid carcinoma (PTC).
APA
Jin T, Ge L, et al. (2023). Identification of iron metabolism-related genes as prognostic indicators for papillary thyroid carcinoma: a retrospective study.. PeerJ, 11, e15592. https://doi.org/10.7717/peerj.15592
MLA
Jin T, et al.. "Identification of iron metabolism-related genes as prognostic indicators for papillary thyroid carcinoma: a retrospective study.." PeerJ, vol. 11, 2023, pp. e15592.
PMID
37361050
Abstract
[BACKGROUND] The thyroid cancer subtype that occurs more frequently is papillary thyroid carcinoma (PTC). Despite a good surgical outcome, treatment with traditional antitumor therapy does not offer ideal results for patients with radioiodine resistance, recurrence, and metastasis. The evidence for the connection between iron metabolism imbalance and cancer development and oncogenesis is growing. Nevertheless, the iron metabolism impact on PTC prognosis is still indefinite.
[METHODS] Herein, we acquired the medical data and gene expression of individuals with PTC from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database. Typically, three predictive iron metabolism-related genes (IMRGs) were examined and employed to build a risk score (RS) model the least absolute shrinkage and selection operator (LASSO) regression, univariate Cox, and differential gene expression analyses. Then we analyzed somatic mutation and immune cell infiltration among RS groups. We also validated the prognostic value of two IMRGs (SFXN3 and TFR2) by verifying their biological function through experiments.
[RESULTS] Based on RS, all patients with PTC were stratified into low- and high-risk groups, where Kaplan-Meier analysis indicated that disease-free survival (DFS) in the high-risk group was much lower than in the low-risk group ( < 0.0001). According to ROC analysis, the RS model successfully predicted the 1-, 3-, and 5-year DFS of individuals with PTC. Additionally, in the TCGA cohort, a nomogram model with RS was developed and exhibited a strong capability to anticipate PTC patients' DFS. In the high-risk group, the enriched pathological processes and signaling mechanisms were detected utilizing the gene set enrichment analysis (GSEA). Moreover, the high-risk group had a significantly higher level of BRAF mutation frequency, tumor mutation burden, and immune cell infiltration than the low-risk group. experiments found that silencing SFXN3 or TFR2 significantly reduced cell viability.
[CONCLUSION] Collectively, our predictive model depended on IMRGs in PTC, which could be potentially utilized to predict the PTC patients' prognosis, schedule follow-up plans, and provide potential targets against PTC.
[METHODS] Herein, we acquired the medical data and gene expression of individuals with PTC from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database. Typically, three predictive iron metabolism-related genes (IMRGs) were examined and employed to build a risk score (RS) model the least absolute shrinkage and selection operator (LASSO) regression, univariate Cox, and differential gene expression analyses. Then we analyzed somatic mutation and immune cell infiltration among RS groups. We also validated the prognostic value of two IMRGs (SFXN3 and TFR2) by verifying their biological function through experiments.
[RESULTS] Based on RS, all patients with PTC were stratified into low- and high-risk groups, where Kaplan-Meier analysis indicated that disease-free survival (DFS) in the high-risk group was much lower than in the low-risk group ( < 0.0001). According to ROC analysis, the RS model successfully predicted the 1-, 3-, and 5-year DFS of individuals with PTC. Additionally, in the TCGA cohort, a nomogram model with RS was developed and exhibited a strong capability to anticipate PTC patients' DFS. In the high-risk group, the enriched pathological processes and signaling mechanisms were detected utilizing the gene set enrichment analysis (GSEA). Moreover, the high-risk group had a significantly higher level of BRAF mutation frequency, tumor mutation burden, and immune cell infiltration than the low-risk group. experiments found that silencing SFXN3 or TFR2 significantly reduced cell viability.
[CONCLUSION] Collectively, our predictive model depended on IMRGs in PTC, which could be potentially utilized to predict the PTC patients' prognosis, schedule follow-up plans, and provide potential targets against PTC.
MeSH Terms
Humans; Thyroid Cancer, Papillary; Prognosis; Retrospective Studies; Iodine Radioisotopes; Thyroid Neoplasms; Iron
같은 제1저자의 인용 많은 논문 (5)
- -Targeted Neoadjuvant Therapy Enables Curative Surgery in an Ultra-Elderly Patient With Recurrent Colon Cancer Harboring a CCDC6-RET Fusion.
- PTPN22 Dephosphorylates CBL to Inhibit PD-L1 Ubiquitination and Drive Immunosuppression in Renal Cell Carcinoma.
- Asymptomatic Lung Adenocarcinoma With Cardiac Metastasis at Initial Diagnosis: A Case Report.
- BUB1/KIF14 complex promotes anaplastic thyroid carcinoma progression by inducing chromosome instability.
- The expression of two immunosuppressive SIGLEC family molecules in papillary thyroid cancer and their effect on prognosis.